disodium;dioxido-oxo-sulfanylidene-λ6-sulfane

• 分子结构分类: 无机化合物 - 混合金属/非金属化合物 - 碱金属含氧阴离子化合物
• 英文名称: disodium;dioxido-oxo-sulfanylidene-λ6-sulfane
• 化学式: Na2O3S2
• 分子量: 158.11
• InChiKey: AKHNMLFCWUSKQB-UHFFFAOYSA-L

计算性质

• 辛醇/水分配系数(LogP)：
  -7.0
• 重原子数：
  7
• 可旋转键数：
  0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  104
• 氢给体数：
  0
• 氢受体数：
  4

ADMET

毒理性

• 药物性肝损伤

硫酸钠

Compound:sodium thiosulfate

来源:Drug Induced Liver Injury Rank (DILIrank) Dataset

毒理性

• 药物性肝损伤

DILI 注解：无 DILI（药物性肝损伤）担忧

DILI Annotation:No-DILI-Concern

来源:Drug Induced Liver Injury Rank (DILIrank) Dataset

毒理性

• 药物性肝损伤

标签部分：无匹配

Label Section:No match

来源:Drug Induced Liver Injury Rank (DILIrank) Dataset

毒理性

• 药物性肝损伤

参考文献：M Chen, V Vijay, Q Shi, Z Liu, H Fang, W Tong. 美国食品药品监督管理局批准的药物标签用于研究药物诱导的肝损伤，《药物发现今日》，16(15-16):697-703, 2011. PMID:21624500 DOI:10.1016/j.drudis.2011.05.007 M Chen, A Suzuki, S Thakkar, K Yu, C Hu, W Tong. DILIrank：按人类发展药物诱导肝损伤风险排名的最大参考药物清单。《药物发现今日》2016, 21(4): 648-653. PMID:26948801 DOI:10.1016/j.drudis.2016.02.015

References:M Chen, V Vijay, Q Shi, Z Liu, H Fang, W Tong. FDA-Approved Drug Labeling for the Study of Drug-Induced Liver Injury, Drug Discovery Today, 16(15-16):697-703, 2011. PMID:21624500 DOI:10.1016/j.drudis.2011.05.007 M Chen, A Suzuki, S Thakkar, K Yu, C Hu, W Tong. DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug Discov Today 2016, 21(4): 648-653. PMID:26948801 DOI:10.1016/j.drudis.2016.02.015

来源:Drug Induced Liver Injury Rank (DILIrank) Dataset

毒理性

• 在妊娠和哺乳期间的影响

哺乳期使用概述：目前没有关于哺乳期间使用硫代硫酸钠的临床信息。然而，它不会通过口服吸收，报告的口服副作用是腹泻。在服用一剂后，停止哺乳1到2小时应该能让药物从母体血液和母乳中清除。观察婴儿是否有腹泻。 对哺乳婴儿的影响：截至修订日期，没有找到相关的已发布信息。 对泌乳和母乳的影响：截至修订日期，没有找到相关的已发布信息。

◉ Summary of Use during Lactation:No information is available on the clinical use of sodium thiosulfate during breastfeeding. However, it is not absorbed orally and the reported side effect after oral use is diarrhea. Withholding breastfeeding for 1 to 2 hours after a dose should allow the drug to be cleared from the maternal bloodstream and breastmilk. Observe the infant for diarrhea. ◉ Effects in Breastfed Infants:Relevant published information was not found as of the revision date. ◉ Effects on Lactation and Breastmilk:Relevant published information was not found as of the revision date.

来源:Drugs and Lactation Database (LactMed)

吸收、分配和排泄

肠道吸收不良。... 硫代硫酸盐离子在细胞外液中分布。

POORLY ABSORBED FROM BOWEL. ... THIOSULFATE ION DISTRIBUTES ITSELF IN EXTRACELLULAR FLUID.

来源:Hazardous Substances Data Bank (HSDB)

反应信息

• 作为反应物：
  描述：

  disodium;dioxido-oxo-sulfanylidene-λ6-sulfane 生成 氢氧化铟
  参考文献：
  名称：

  OTO, SYUITI;YAMAKI, TORUO

  摘要：

  DOI：
• 作为产物：
  描述：

  硫化氢 生成 disodium;dioxido-oxo-sulfanylidene-λ6-sulfane
  参考文献：
  名称：

  GALANIN, I. A.;ZINOVEVA, N. M.;SHESTERIKOVA, R. E.;LI, G. P.;BASOVA, A. G+

  摘要：

  DOI：
• 作为试剂：
  描述：

  1-Chlor-4-cyclopentyl-1-trans-buten-3-on 、 碘化钠 、 在 乙醚 、 水 、 disodium;dioxido-oxo-sulfanylidene-λ6-sulfane 、 氯化钠 、 硫酸酯 作用下， 以 丙酮 为溶剂， 反应 18.0h， 以to give 87 g的产率得到4-Cyclopentyl-1-iodo-trans-buten-3-one
  参考文献：
  名称：

  Novel prostaglandins

  摘要：

  本披露描述了具有抗溃疡、支气管扩张和降压活性的新型15-羟基前列腺酸衍生物。

  公开号：

  US04180677A1

文献信息

• FUSED HETEROAROMATIC PYRROLIDINONES
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US20150336964A1

  公开（公告）日：2015-11-26

  Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein G, L 1 , L 2 , R 1 , R 2 , R 3 , and R 4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, pharmaceutical compositions containing them, and their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other disorders, diseases, and conditions for which inhibition of SYK is indicated.

  本文披露了公式1的化合物及其药学上可接受的盐，其中G、L1、L2、R1、R2、R3和R4在规范中有定义。本文还涉及制备公式1化合物的材料和方法，包含它们的药物组合物，以及它们用于治疗涉及免疫系统和炎症的疾病、疾病和状况，包括类风湿性关节炎、血液恶性肿瘤、上皮癌（即癌症）和其他需要抑制SYK的疾病、疾病和状况。
• PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS
  申请人：Bell Ian M.

  公开号：US20120122899A1

  公开（公告）日：2012-05-17

  The present invention is directed to piperidinone carboxamide azaindane derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  本发明涉及吡啶酮羧酰胺吡嗪衍生物，其为CGRP受体拮抗剂，可用于治疗或预防CGRP参与的疾病，如偏头痛。本发明还涉及包含这些化合物的药物组合物以及在预防或治疗CGRP参与的这些疾病中使用这些化合物和组合物。
• Cathepsin inhibitors
  申请人：Bayly Christopher

  公开号：US20060287402A1

  公开（公告）日：2006-12-21

  This invention relates to a novel class of compounds, represented by the formula (I) below, wherein the meanings of R 1 , R 2 , R 3 and R 4 are indicated therein, which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis, osteoarthritis and rheumatoid arthritis.

  本发明涉及一类新型化合物，其公式表示为(I)，其中R1、R2、R3和R4的含义如下所示，它们是半胱氨酸蛋白酶抑制剂，包括但不限于对卡特普西林K、L、S和B的抑制剂。这些化合物可用于治疗需要抑制骨吸收的疾病，例如骨质疏松症、骨关节炎和类风湿性关节炎。
• Azetidines
  申请人：Dack Kevin Neil

  公开号：US20080280877A1

  公开（公告）日：2008-11-13

  The invention relates to EP2 antagonist azetidines of formula (I) wherein Ar, R 1 , X, and Z are as defined herein, to their use in medicine, particularly in the treatment of endometriosis and/or uterine fibroids, to intermediates useful in their synthesis, and to compositions containing them.

  本发明涉及公式（I）的EP2拮抗剂氮杂环丙烷，其中Ar，R1，X和Z如本文所定义，以及它们在医学上的应用，特别是在治疗子宫内膜异位症和/或子宫肌瘤方面的应用，以及在它们的合成中有用的中间体和包含它们的组合物。
• 1H-QUINAZOLINE-2,4-DIONES
  申请人：NOVARTIS AG

  公开号：US20130296332A1

  公开（公告）日：2013-11-07

  The present invention relates to 1H-Quinazoline-2,4-diones of formula (I) wherein R 1 and R 2 are as defined in the specification, their preparation, their use as pharmaceuticals, and pharmaceutical compositions containing them. Further, intermediates for the manufacture of compounds of formula (I) are and combinations comprising compounds of formula (I) are disclosed.

  本发明涉及公式(I)的1H-喹唑啉-2,4-二酮，其中R1和R2如规范所定义，它们的制备，它们作为药物的用途，以及含有它们的药物组合物。此外，还公开了制造公式(I)化合物的中间体和包含公式(I)化合物的组合物。

表征谱图